Literature DB >> 24133576

Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk.

Anja Rogler1, Sabine Hoja, Eileen Socher, Elke Nolte, Sven Wach, Wolf Wieland, Ferdinand Hofstädter, Peter J Goebell, Bernd Wullich, Arndt Hartmann, Robert Stoehr.   

Abstract

In this study, we determined the genotype distribution of two single nucleotide polymorphisms (SNPs) in secreted frizzled related protein 1 (SFRP1), rs3242 and rs921142, in a Caucasian bladder cancer case-control study. Allelic variants of the SNPs were determined using restriction fragment length polymorphism (RFLP) analysis and partly verified by sequencing analysis. Overall, DNA from 188 consecutive and 215 early-onset bladder cancer patients (≤45 years) as well as from 332 controls was investigated. Potential microRNA binding sites were determined for rs3242, and microRNA expression was analysed in cell lines and tumour specimens. We observed a remarkable distribution difference in rs3242 between bladder cancer patients and healthy controls (p=0.05). Additionally, we found a significant difference in genotype distribution (p=0.032), resulting from the difference of early-onset patients and the control group (p=0.007). The risk allele T showed increased frequency in the early-onset patient group (p=0.002). Genotype-dependent differences of microRNA binding capacity were predicted in SFRP1 mRNA for two microRNAs. Hsa-miR-3646 showed strong expression in cell lines and tumour tissue, whereas hsa-miR-603 exhibited weak expression. The rs921142 SNP showed no significant association with bladder cancer risk. This is the first study to describe an association of the SFRP1 SNP rs3242 and bladder cancer risk as well as the influence of rs3242 on genotype-dependent microRNA capacity on SFRP1 mRNA. The onset of bladder seems to be associated with the increased occurrence of the T-allele in rs3242.

Entities:  

Keywords:  SFRP1; SNP; Wnt signalling pathway; bladder cancer; microRNA

Mesh:

Substances:

Year:  2013        PMID: 24133576      PMCID: PMC3796220     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  34 in total

1.  MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia.

Authors:  R M Swinney; S C Hsu; B A Hirschman; T T-C Chen; G E Tomlinson
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

2.  The transcripts of SFRP1,CEP63 and EIF4G2 genes are frequently downregulated in transitional cell carcinomas of the bladder.

Authors:  Marcilei E Buim; Fernando A Soares; Alvaro S Sarkis; Maria Aparecida Nagai
Journal:  Oncology       Date:  2006-01-12       Impact factor: 2.935

3.  Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Authors:  J R Masters; P J Hepburn; L Walker; W J Highman; L K Trejdosiewicz; S Povey; M Parkar; B T Hill; P R Riddle; L M Franks
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

4.  Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan.

Authors:  C C Tzeng; H S Liu; C Li; Y T Jin; R M Chen; W H Yang; J S Lin
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

5.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

Review 6.  WNT and beta-catenin signalling: diseases and therapies.

Authors:  Randall T Moon; Aimee D Kohn; Giancarlo V De Ferrari; Ajamete Kaykas
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

7.  The Wnt antagonist sFRP1 in colorectal tumorigenesis.

Authors:  Germaine M Caldwell; Carolyn Jones; Karl Gensberg; Shamem Jan; Robert G Hardy; Philip Byrd; Shaheen Chughtai; Yvonne Wallis; Glenn M Matthews; Dion G Morton
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

8.  Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.

Authors:  Chiara Menin; Maria Chiara Scaini; Gian Luca De Salvo; Martina Biscuola; Monica Quaggio; Giovanni Esposito; Claudio Belluco; Marco Montagna; Simona Agata; Emma D'Andrea; Donato Nitti; Alberto Amadori; Roberta Bertorelle
Journal:  J Natl Cancer Inst       Date:  2006-02-15       Impact factor: 13.506

9.  Hedgehog pathway activation in human transitional cell carcinoma of the bladder.

Authors:  G Pignot; A Vieillefond; S Vacher; M Zerbib; B Debre; R Lidereau; D Amsellem-Ouazana; I Bieche
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

10.  Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression.

Authors:  K M Rieger; A F Little; J M Swart; W V Kastrinakis; J M Fitzgerald; D T Hess; J A Libertino; I C Summerhayes
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more
  10 in total

Review 1.  Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases.

Authors:  Z-M Wang; J-Q Luo; L-Y Xu; H-H Zhou; W Zhang
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

2.  miR-3646 promotes cell proliferation, migration, and invasion via regulating G2/M transition in human breast cancer cells.

Authors:  Shuang Tao; Yao-Bang Liu; Zhi-Wei Zhou; Bin Lian; Hong Li; Jin-Ping Li; Shu-Feng Zhou
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

3.  Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis.

Authors:  You-Cheng Lin; Xun Wu; Xue-Qiong Zhou; Rui Ren; Ze-Xuan Su; Chun-Xiao Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin.

Authors:  Ana Herman; Kristina Gruden; Andrej Blejec; Vid Podpečan; Helena Motaln; Primož Rožman; Matjaž Hren; Klemen Zupančič; Matija Veber; Urška Verbovšek; Tamara Lah Turnšek; Andrej Porčnik; Marjan Koršič; Miomir Knežević; Matjaž Jeras
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

5.  Association of genetic variations in the Wnt signaling pathway genes with myocardial infarction susceptibility in Chinese Han population.

Authors:  Jing Tao; Yong-Tao Wang; Mayila Abudoukelimu; Yi-Ning Yang; Xiao-Mei Li; Xiang Xie; Bang-Dang Chen; Fen Liu; Chun-Hui He; Hua-Yin Li; Yi-Tong Ma
Journal:  Oncotarget       Date:  2016-08-16

6.  Bioinformatics analysis of dysregulated microRNAs in the nipple discharge of patients with breast cancer.

Authors:  Kai Zhang; Ya-Wen Wang; Rong Ma
Journal:  Oncol Lett       Date:  2017-03-03       Impact factor: 2.967

Review 7.  Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance.

Authors:  Nilay Mitash; Swasti Tiwari; Shalini Agnihotri; Anil Mandhani
Journal:  Indian J Urol       Date:  2017 Apr-Jun

8.  MicroRNA miR-3646 promotes malignancy of lung adenocarcinoma cells by suppressing sorbin and SH3 domain-containing protein 1 via the c-Jun NH2-terminal kinase signaling pathway.

Authors:  Chun Wang; Bo Cheng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

9.  Association of genetic variants in Wnt signaling pathway with tuberculosis in Chinese Han population.

Authors:  Xuejiao Hu; Mengqiao Shang; Juan Zhou; Yuanxin Ye; Xiaojun Lu; Chuanmin Tao; Binwu Ying; Lanlan Wang
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

10.  MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway.

Authors:  Xiaohui Zhang; Shanliang Zhong; Yong Xu; Dandan Yu; Tengfei Ma; Lin Chen; Yang Zhao; Xiu Chen; Sujin Yang; Yueqin Wu; Jinhai Tang; Jianhua Zhao
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.